Press Releases

Taro CEO Kal Sundaram to Return to Sun Pharma Headquarters by the End of 2016

Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (“Taro” or the “Company”) announced that its CEO, Mr. Kal Sundaram, has informed Taro’s Board of Directors (“Board”) of his intention to step down as CEO by the end of the current calendar year. Mr. Sundaram will return to India, to assume an executive position at Sun Pharma’s global headquarters after the completion of his assignment at Taro at the end of 2016.

The Company’s Board will conduct a formal process to appoint a CEO to solely focus on Taro. Mr. Sundaram will assist the Board with its search, and will remain with Taro through the end of 2016 to ensure a smooth and successful transition for his successor.

Commenting on the transition, Mr. Dilip Shanghvi, Taro’s Chairman said, “On behalf of Taro’s entire Board, I want to thank Kal for his many contributions to Taro – providing significant leadership over a challenging period for both the company and the industry, his commitment and dedication to being a driving force behind Taro’s strategic direction, and leading the company on a steady and consistent growth path – delivering strong financial and operational performance.”

Mr. Sundaram added, “I am grateful and privileged to be associated with Taro for the past four years as a Board member and three years as CEO. I am also proud of what the Taro team has accomplished during that time. By all measures, the Company has executed very well over the past several years, and as a result, Taro is well positioned for continued growth and success.” Mr. Sundaram concluded, “I’d like to thank the Board, the executive management team, and Taro’s employees for their support throughout the years.”

About Taro

Taro Pharmaceutical Industries Ltd. is a multinational, science-based pharmaceutical company, dedicated to meeting the needs of its customers through the discovery, development, manufacturing and marketing of the highest quality healthcare products. For further information on Taro Pharmaceutical Industries Ltd., please visit the Company’s website at www.taro.com.

SAFE HARBOR STATEMENT

Certain statements in this press release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.These statements include, but are not limited to, statements that do not describe historical facts and statements that refer or relate to events or circumstances Taro “estimates,” “believes,” or “expects” to happen or similar language.The forward-looking statements in this press release are based on Taro’s current expectations and are made only as of the date of this press release and involve certain risks and uncertainties that could cause actual results to differ materially from future results that may be expressed or implied by such forward-looking statements.Unless required by law, Taro undertakes no obligations to update, change or revise any forward-looking statement, whether as a result of new information, additional or subsequent developments or otherwise.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160706006374/en/

Show More

Related Articles

Close

Adblock Detected

Please consider supporting us by disabling your ad blocker